文献速递生殖医学妇科母胎医学

孕前基因组医学:基于个体基因组数据改善不孕症诊断与生殖健康结局的现状与未来展望

Preconception genome medicine: current state and future perspectives to improve infertility diagnosis and reproductive and health outcomes based on individual genomic data.
PubMed 文献 · Hum Reprod Update · 2021-01-01

本文综述孕前基因组分析在生殖与个体健康风险评估中的应用,包括隐性遗传病携带筛查、医学可干预的继发发现及IVF相关生殖结局预测。孕前基因组测序可识别约4%备孕夫妇的遗传病携带,2-4%个体晚发型可干预疾病的遗传风险,并推动不孕症精准生殖医学的发展。

要点

  • 孕前基因组测序可识别约4%备孕夫妇的隐性遗传病携带状态。
  • 约2-4%个体可通过基因组信息预判晚发型医学可干预疾病风险。
  • 基因组变异与IVF药物反应及精子、卵母细胞、胚胎发育异常相关。

核心结论

  • 孕前基因组分析可扩展至生殖表型预测、药物基因组学和分子胚胎学,推动不孕症精准医学发展。

研究设计与样本

  • 本文为综述,检索PubMed Central,使用人类、遗传学、基因组学、变异、男性、女性、生育力、下一代测序、全基因组外显子测序、扩展性携带筛查、继发发现、药物基因组学、控制性卵巢刺激、孕前、全基因组关联研究等MeSH词组合。

主要发现

  • 通过PubMed Central检索共识别1409篇文章,限定2004年以来发表,经标题相关性评估后剩余644篇。
  • 孕前基因组测序可识别约4%备孕夫妇基因组中隐藏的可遗传遗传病。
  • 基因组信息可预判约2-4%个体具有强遗传背景的晚发型医学可干预疾病。
  • 已发现与IVF药物治疗差异反应相关的遗传变异,以及异常精子类型、卵母细胞成熟、受精或植入前后胚胎发育的明确基因型-表型关联。

临床怎么用

  • 孕前基因组测序可用于备孕夫妇的隐性遗传病携带筛查和医学可干预继发发现评估。
  • 对不孕症患者进行基因组测序有助于识别目前定义为「不明原因」的不孕遗传病因。
  • 基因组信息可指导IVF个体化用药及预测特定生殖结局,如卵巢早衰倾向、非整倍体风险、卵母细胞完全不成熟或囊胚发育失败。

局限性

  • 综述未报告孕前基因组测序在临床实施中尚存和即将面临的具体障碍内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our genetic code is now readable, writable and hackable. The recent escalation of genome-wide sequencing (GS) applications in population diagnostics will not only enable the assessment of risks of transmitting well-defined monogenic disorders at preconceptional stages (i.e. carrier screening), but also facilitate identification of multifactorial genetic predispositions to sub-lethal pathologies, including those affecting reproductive fitness. Through GS, the acquisition and curation of reproductive-related findings will warrant the expansion of genetic assessment to new areas of genomic prediction of reproductive phenotypes, pharmacogenomics and molecular embryology, further boosting our knowledge and therapeutic tools for treating infertility and improving women's health. OBJECTIVE AND RATIONALE: In this article, we review current knowledge and potential development of preconception genome analysis aimed at detecting reproductive and individual health risks (recessive genetic disease and medically actionable secondary findings) as well as anticipating specific reproductive outcomes, particularly in the context of IVF. The extension of reproductive genetic risk assessment to the general population and IVF couples will lead to the identification of couples who carry recessive mutations, as well as sub-lethal conditions prior to conception. This approach will provide increased reproductive autonomy to couples, particularly in those cases where preimplantation genetic testing is an available option to avoid the transmission of undesirable conditions. In addition, GS on prospective infertility patients will enable genome-wide association studies specific for infertility phenotypes such as predisposition to premature ovarian failure, increased risk of aneuploidies, complete oocyte immaturity or blastocyst development failure, thus empowering the development of true reproductive precision medicine. SEARCH METHODS: Searches of the literature on PubMed Central included combinations of the following MeSH terms: human, genetics, genomics, variants, male, female, fertility, next generation sequencing, genome exome sequencing, expanded carrier screening, secondary findings, pharmacogenomics, controlled ovarian stimulation, preconception, genetics, genome-wide association studies, GWAS. OUTCOMES: Through PubMed Central queries, we identified a total of 1409 articles. The full list of articles was assessed for date of publication, limiting the search to studies published within the last 15 years (2004 onwards due to escalating research output of next-generation sequencing studies from that date). The remaining articles' titles were assessed for pertinence to the topic, leaving a total of 644 articles. The use of preconception GS has the potential to identify inheritable genetic conditions concealed in the genome of around 4% of couples looking to conceive. Genomic information during reproductive age will also be useful to anticipate late-onset medically actionable conditions with strong genetic background in around 2-4% of all individuals. Genetic variants correlated with differential response to pharmaceutical treatment in IVF, and clear genotype-phenotype associations are found for aberrant sperm types, oocyte maturation, fertilization or pre- and post-implantation embryonic development. All currently known capabilities of GS at the preconception stage are reviewed along with persisting and forthcoming barriers for the implementation of precise reproductive medicine. WIDER IMPLICATIONS: The expansion of sequencing analysis to additional monogenic and polygenic traits may enable the development of cost-effective preconception tests capable of identifying underlying genetic causes of infertility, which have been defined as 'unexplained' until now, thus leading to the development of a true personalized genomic medicine framework in reproductive health.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Capalbo A, Poli M, Riera-Escamilla A, et al. Preconception genome medicine: current state and future perspectives to improve infertility diagnosis and reproductive and health outcomes based on individual genomic data. Hum Reprod Update. 2021. PMID: 33197264. doi:10.1093/humupd/dmaa044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。